The MBZ concentration required to inhibit the GLI promoter activity was within clinically achievable concentrations, with an IC50 ranging from 32 ± 20 to 267 ± 71 nM after 48 h in the AML cell lines tested (Figure 1C). The gene discussed is GLI1; the disease is acute myeloid leukemia.